• 1
    Koshimune R,Aoe M,Toyooka S,Hara F,Ouchida M,Tokumo M,Sano Y,Date H,Shimizu N. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. Cancer 2007; 12: 78.
  • 2
    Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 158894.
  • 3
    Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 121825.
  • 4
    Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42: 895906.
  • 5
    Kohno N,Aogi K,Minami H,Nakamura S,Asaga T,Iino Y,Watanabe T,Goessl C,Ohashi Y,Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 331421.
  • 6
    Rosen LS,Gordon D,Kaminski M,Howell A,Belch A,Mackey J,Apffelstaedt J,Hussein MA,Coleman RE,Reitsma DJ,Chen BL,Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 173544.
  • 7
    Rogers MJ,Watts DJ,Russel RG. Overview of bisphosphonates. Cancer 1997; 80: 165260.
  • 8
    Coleman RE. Management of bone metastases. Oncologist 2000; 5: 46370.
  • 9
    Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97 ( Suppl 3): 8407.
  • 10
    Matsumoto S,Kimura S,Segawa H,Kuroda J,Yuasa T,Sato K,Nogawa M,Tanaka F,Maekawa T,Wada H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines. Lung Cancer 2005; 47: 319.
  • 11
    Berger W,Kubista B,Elbling L,Sutterluty H,Micksche M. The N-containing bisphosphonate zoledronic acid exerts potent anticancer activity against non-small cell lung cancer cells by inhibition of protein geranylgeranylation. Proc Am Assoc Cancer Res 2005; 46 (Abst 4981) AACR Meeting Abstracts 2005:1176-c.
  • 12
    Demers LM,Costa L,Chinchilli VM,Gaydos L,Curley E,Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 148994.
  • 13
    Brown JE,Cook RJ,Major P,Lipton A,Saad F,Smith M,Lee KA,Zheng M,Hei YJ,Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 5969.
  • 14
    Lipton A,Costa L,Ali SM,Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001; 27: 1815.
  • 15
    Costa L,Demers LM,Gouveia-Oliveira A,Schaller J,Costa EB,de Moura MC,Lipton A. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20: 8506.
  • 16
    Demers LM,Costa L,Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88: 291926.
  • 17
    Vinholes JJ,Purohit OP,Abbey ME,Eastell R,Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 124350.
  • 18
  • 19
    Aapro M,Abrahamsson PA,Body JJ,Coleman RE,Colomer R,Costa L,Crinò L,Dirix L,Gnant M,Gralow J,Hadji P,Hortobagyi GN, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 42032.
  • 20
    Berenson J,Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004; 9: 31929.
  • 21
    Cleeland CS,Ryan KM. Bone pain inventory. Ann Acad Med Singapore 1994; 23: 12938.
  • 22
    Ibrahim T,Barbanti F,Giorgio-Marrano G,Mercatali L,Ronconi S. Oncologist 2008; 13: 3306.
  • 23
    Jagdev SP,Coleman RE,Shipman CM,Rostami HA,Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 112634.
  • 24
    Neville-Webbe HL,Evans CA,Coleman RE,Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92103.
  • 25
    Vogt U,Bielawski KP,Bosse U,Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12: 110914.
  • 26
    Coleman RE,Major P,Lipton A,Brown JE,Lee KA,Smith M,Saad F,Zheng M,Hei YJ,Seaman J,Cook R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 48212.
  • 27
    Caraglia M,Santini D,Marra M,Vincenzi B,Tonini G,Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13: 726.
  • 28
    Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007; 6: 30513.
  • 29
    Rosen LS,Gordon D,Tchekmedyian NS,Yanagihara R,Hirsh V,Krzakowski M,Pawlicki M,De Souza P,Zheng M,Urbanowitz G,Reitsma D,Seaman J. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in pts with nonsmall cell lung carcinoma and other solid tumors: arandomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 261321.
  • 30
    Guarneri V,Donati S,Nicolini M,Giovanelli S. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 8428.
  • 31
    Ali SM,Esteva FJ,Hortobagyi G,Harvey H,Seaman J,Knight R,Costa L,Lipton A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 34347.